综述:迈向克罗恩病与类风湿关节炎的共同治疗目标
该综述检索1982年至2016年文献,比较克罗恩病与类风湿关节炎的治疗目标。两者均采用评估结构损伤与残疾、紧密控制、达标治疗、早期干预和疾病修饰策略;但克罗恩病缺乏疾病修饰试验,多数策略需前瞻性研究验证。
要点
- 克罗恩病治疗目标已从单纯控制症状转为临床缓解联合完全黏膜愈合(深度缓解)。
- 类风湿关节炎与克罗恩病共同策略包括评估损伤与残疾、紧密控制、达标治疗、早期干预和疾病修饰。
- 克罗恩病疾病修饰试验匮乏,多数策略需前瞻性研究验证。
核心结论
- 基于紧密控制客观炎症标志物的克罗恩病新治疗策略有望通过阻止进展或理想地预防肠损伤发生来改变疾病进程和患者生活。
- 多数此类策略需前瞻性研究验证,而类风湿关节炎近十年已有若干疾病修饰试验探讨这些问题。
- 近期获批的维得利珠单抗和乌司奴单抗应有助于近期启动克罗恩病疾病修饰试验。
研究设计与样本
- 综述分析了1982年至2016年间讨论和/或提出克罗恩病与类风湿关节炎治疗目标及其支持证据的文献。
主要发现
- 克罗恩病与类风湿关节炎均为慢性、进展性和致残性疾病,常导致结构性组织损伤。
- 改善类风湿关节炎和克罗恩病结局的拟议治疗策略包括评估肌肉骨骼或器官损伤与残疾、紧密控制、达标治疗、早期干预和疾病修饰。
- 与类风湿关节炎相比,克罗恩病疾病修饰试验匮乏。
局限性
- 与类风湿关节炎相比,克罗恩病疾病修饰试验匮乏。
- 多数克罗恩病新治疗策略需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis. METHODS: This review examined manuscripts from 1982 to 2016 that discussed and/or proposed therapeutic goals with their supportive evidence in CD and rheumatoid arthritis. RESULTS: Proposed therapeutic strategies to improve outcomes in both rheumatoid arthritis and CD include: (i) evaluation of musculoskeletal or organ damage and disability, (ii) tight control, (iii) treat-to-target, (iv) early intervention and (v) disease modification. In contrast to rheumatoid arthritis, there is a paucity of disease-modification trials in CD. CONCLUSIONS: Novel therapeutic strategies in CD based on tight control of objective signs of inflammation are expected to change disease course and patients' lives by halting progression or, ideally, preventing the occurrence of bowel damage. Most of these strategies require validation in prospective studies, whereas several disease-modification trials have addressed these issues in rheumatoid arthritis over the last decade. The recent approval of new drugs in CD such as vedolizumab and ustekinumab should facilitate initiation of disease-modification trials in CD in the near future.
引用
- Allen PB, Olivera P, Emery P, et al. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017. PMID: 28247573. doi:10.1111/apt.13995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。